BRPI1013626A2 - método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico - Google Patents
método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específicoInfo
- Publication number
- BRPI1013626A2 BRPI1013626A2 BRPI1013626A BRPI1013626A BRPI1013626A2 BR PI1013626 A2 BRPI1013626 A2 BR PI1013626A2 BR PI1013626 A BRPI1013626 A BR PI1013626A BR PI1013626 A BRPI1013626 A BR PI1013626A BR PI1013626 A2 BRPI1013626 A2 BR PI1013626A2
- Authority
- BR
- Brazil
- Prior art keywords
- physiologically active
- active polypeptide
- polypeptide conjugate
- specific physiologically
- preparing site
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0023953 | 2009-03-20 | ||
KR20090023953 | 2009-03-20 | ||
PCT/KR2010/001674 WO2010107256A2 (en) | 2009-03-20 | 2010-03-18 | Method for preparing a site-specific physiologically active polypeptide conjugate |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI1013626A2 true BRPI1013626A2 (pt) | 2016-04-19 |
BRPI1013626B1 BRPI1013626B1 (pt) | 2021-05-11 |
BRPI1013626B8 BRPI1013626B8 (pt) | 2021-05-25 |
Family
ID=42740133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1013626A BRPI1013626B8 (pt) | 2009-03-20 | 2010-03-18 | método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico |
Country Status (25)
Country | Link |
---|---|
US (1) | US8895281B2 (pt) |
EP (1) | EP2408800B1 (pt) |
JP (2) | JP5759976B2 (pt) |
KR (1) | KR101164453B1 (pt) |
CN (1) | CN102369209B (pt) |
AR (1) | AR075913A1 (pt) |
AU (1) | AU2010225523B2 (pt) |
BR (1) | BRPI1013626B8 (pt) |
CA (1) | CA2755395C (pt) |
DK (1) | DK2408800T3 (pt) |
ES (1) | ES2587397T3 (pt) |
HK (1) | HK1163120A1 (pt) |
HR (1) | HRP20161055T1 (pt) |
HU (1) | HUE030373T2 (pt) |
IL (1) | IL215165A (pt) |
MX (1) | MX2011009803A (pt) |
MY (1) | MY150536A (pt) |
NZ (1) | NZ595848A (pt) |
PL (1) | PL2408800T3 (pt) |
PT (1) | PT2408800T (pt) |
RU (1) | RU2495881C2 (pt) |
SG (1) | SG174320A1 (pt) |
TW (1) | TWI472342B (pt) |
WO (1) | WO2010107256A2 (pt) |
ZA (1) | ZA201107658B (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012046845A1 (ja) * | 2010-10-08 | 2012-04-12 | 国立大学法人京都大学 | ペプチド誘導体及びその使用 |
US9278146B2 (en) | 2010-10-08 | 2016-03-08 | Kyoto University | Peptide derivative and use of the same |
CN102675452B (zh) * | 2011-03-17 | 2015-09-16 | 重庆富进生物医药有限公司 | 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物 |
CN106928341B (zh) * | 2011-03-30 | 2021-06-01 | 上海仁会生物制药股份有限公司 | 定点单取代聚乙二醇化Exendin类似物及其制备方法 |
US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
KR102092206B1 (ko) * | 2011-06-02 | 2020-03-24 | 옵코 바이오로직스 리미티드 | 장기-작용성 glp-1/글루카곤 수용체 작용제 |
DK3878859T3 (da) | 2011-06-10 | 2024-01-02 | Hanmi Science Co Ltd | Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse |
HUE042585T2 (hu) | 2011-06-17 | 2019-07-29 | Hanmi Science Co Ltd | Oxintomodulint és immunglobulin-fragmentumot tartalmazó konjugátum és alkalmazása |
KR20130049671A (ko) * | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
KR101895047B1 (ko) * | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
KR102092025B1 (ko) | 2012-06-04 | 2020-03-24 | 옵코 바이오로직스 리미티드 | 페길화된 옥신토모둘린 변이체 |
KR101968344B1 (ko) * | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
EP2916819B1 (en) * | 2012-11-06 | 2019-07-10 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
KR20140088837A (ko) * | 2013-01-03 | 2014-07-11 | 한미약품 주식회사 | N-말단 전하가 변형된 인슐린 분비 펩티드 유도체 |
SG11201505615PA (en) * | 2013-02-26 | 2015-09-29 | Hanmi Pharm Ind Co Ltd | Site-specific insulin conjugate |
AR096891A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
CN103804483A (zh) * | 2014-03-13 | 2014-05-21 | 中国人民解放军第四军医大学 | Orexin-A聚乙二醇化修饰物及其制备方法 |
KR20150140177A (ko) * | 2014-06-05 | 2015-12-15 | 한미약품 주식회사 | 단백질 및 펩타이드의 면역원성을 감소시키는 방법 |
TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
CN108026143B (zh) * | 2015-07-24 | 2022-05-27 | 韩美药品株式会社 | 制备生理活性多肽缀合物的方法 |
KR101974305B1 (ko) * | 2018-02-14 | 2019-04-30 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
CN109678930B (zh) * | 2018-12-05 | 2022-04-29 | 西北工业大学 | 聚乙二醇修饰的npff及其用途 |
CN109535244B (zh) * | 2018-12-11 | 2020-12-01 | 上海景峰制药有限公司 | 一种重组人脑利钠肽的纯化方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2204726A1 (en) * | 1994-11-09 | 1996-12-27 | Robin E. Offord | Functionalized polymers for site-specific attachment |
EP0922446A1 (en) * | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
US5981709A (en) * | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
AU775063C (en) | 1999-04-30 | 2005-05-12 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
IL155177A0 (en) * | 2000-10-05 | 2003-11-23 | Ares Trading Sa | Method for the preparation of grf-peg conjugate |
US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US8423976B2 (en) * | 2003-03-13 | 2013-04-16 | Northrop Grumman Corporation | Extreme pipeline and optimized reordering technology |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
PT1605897E (pt) | 2003-03-19 | 2012-09-10 | Lilly Co Eli | Compostos de glp-1 ligado a polietilenoglicol |
KR100507796B1 (ko) | 2003-04-03 | 2005-08-17 | 한미약품 주식회사 | 생체내 반감기가 증가된 peg-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법 |
CN101514223B (zh) * | 2003-04-11 | 2017-03-01 | 安特里阿比奥有限公司 | 位点特异性蛋白质偶联物的制备方法 |
DE602004023626D1 (de) | 2003-08-21 | 2009-11-26 | Novo Nordisk As | Trennung von polypeptiden mit einer racemisierten aminosäure |
CN101124331B (zh) * | 2004-11-12 | 2013-04-24 | 拜尔健康护理有限责任公司 | Fvⅲ的位点定向修饰 |
WO2006076471A2 (en) * | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
WO2008051383A2 (en) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Use of alcohol co-solvents to improve pegylation reaction yields |
JP2009019027A (ja) * | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
-
2010
- 2010-03-18 PT PT107537060T patent/PT2408800T/pt unknown
- 2010-03-18 AU AU2010225523A patent/AU2010225523B2/en active Active
- 2010-03-18 DK DK10753706.0T patent/DK2408800T3/en active
- 2010-03-18 RU RU2011142332/04A patent/RU2495881C2/ru active
- 2010-03-18 US US13/255,199 patent/US8895281B2/en active Active
- 2010-03-18 HU HUE10753706A patent/HUE030373T2/en unknown
- 2010-03-18 BR BRPI1013626A patent/BRPI1013626B8/pt active IP Right Grant
- 2010-03-18 PL PL10753706.0T patent/PL2408800T3/pl unknown
- 2010-03-18 CN CN201080012890.8A patent/CN102369209B/zh active Active
- 2010-03-18 MX MX2011009803A patent/MX2011009803A/es active IP Right Grant
- 2010-03-18 JP JP2012500720A patent/JP5759976B2/ja active Active
- 2010-03-18 SG SG2011065166A patent/SG174320A1/en unknown
- 2010-03-18 KR KR1020100024312A patent/KR101164453B1/ko active IP Right Grant
- 2010-03-18 NZ NZ595848A patent/NZ595848A/en not_active IP Right Cessation
- 2010-03-18 CA CA2755395A patent/CA2755395C/en active Active
- 2010-03-18 ES ES10753706.0T patent/ES2587397T3/es active Active
- 2010-03-18 WO PCT/KR2010/001674 patent/WO2010107256A2/en active Application Filing
- 2010-03-18 EP EP10753706.0A patent/EP2408800B1/en active Active
- 2010-03-18 MY MYPI2011004374 patent/MY150536A/en unknown
- 2010-03-19 TW TW99108144A patent/TWI472342B/zh not_active IP Right Cessation
- 2010-03-22 AR ARP100100911A patent/AR075913A1/es not_active Application Discontinuation
-
2011
- 2011-09-15 IL IL215165A patent/IL215165A/en active IP Right Grant
- 2011-10-19 ZA ZA2011/07658A patent/ZA201107658B/en unknown
-
2012
- 2012-04-05 HK HK12103382.6A patent/HK1163120A1/xx not_active IP Right Cessation
-
2015
- 2015-03-02 JP JP2015040382A patent/JP2015127330A/ja not_active Withdrawn
-
2016
- 2016-08-21 HR HRP20161055TT patent/HRP20161055T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1013626A2 (pt) | método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico | |
IL237642A (en) | METHOD FOR PREPARING PHARMACEUTICAL MATERIALS | |
BR112012000826A2 (pt) | métodos para preparação de vesículas e formulações produzidas a partir dessas | |
BRPI1010717A8 (pt) | armação de dobramento melhorada para um implemento agrícola. | |
BR112013015898A2 (pt) | derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. | |
EP2491931A4 (en) | TRANSDERMAL ABSORBABLE DON-PEPPER PREPARATION | |
BRPI1011764A2 (pt) | composição farmacêutica, e, método para preparar uma composição farmacêutica | |
BR112012000687A2 (pt) | tesoura para um endoscópio | |
BRPI1014035A2 (pt) | método para contracepção. | |
BR112012004395A2 (pt) | liberação de sdf-1 para tratamento do tecido isquêmico | |
UY33094A (es) | Procedimiento para la preparacion de dronedarona | |
BR112012009561A2 (pt) | método para fabricação de manta com suporte poroso e artio poroso com suporte | |
BR112012001819A2 (pt) | métodos para tratamento de dor | |
BR112012016912A2 (pt) | composição de gel de diagnóstico, método para preparar uma composição de gel de diagnóstico | |
ZA201403189B (en) | Method for preparing physiologically active polypeptide complex | |
BRPI0922173A2 (pt) | preparação farmacêutica, e, método para preparar uma preparação farmacêutica | |
BRPI0912099A2 (pt) | preparação percutaneamente absorvível | |
ES2562643T8 (es) | Conjugado de naloxol-peg cristalino | |
EP2476414A4 (en) | TRANSDERMAL ABSORBABLE PREPARATION | |
BRPI1013079A2 (pt) | hidrofobinas para dispersao de agentes ativos | |
BRPI1007320A2 (pt) | Método para preparar nitrotetrazolato de cobre | |
EP2423311A4 (en) | METHOD FOR PRODUCING A CELL PHARMACEUTICALS | |
IL219948A0 (en) | Polypeptide conjugate | |
BR112013013415A2 (pt) | composição farmacêutica, e, método para a preparação de uma composição | |
EP2657336A4 (en) | BIOASSAY PROCEDURE FOR DETECTING A PHYSIOLOGICALLY ACTIVE SUBSTANCE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: HANMI SCIENCE CO., LTD. (KR) |
|
B25G | Requested change of headquarter approved |
Owner name: HANMI SCIENCE CO., LTD. (KR) |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |